Cyclic peptide analogs of 558-565 epitope of A2 subunit of Factor VIII prolong aPTT. Toward a novel synthesis of anticoagulants

C. Anastasopoulos, Y. Sarigiannis, G. Stavropoulos

Research output: Contribution to journalArticlepeer-review

Abstract

Novel anticoagulant therapies target specific clotting factors in blood coagulation cascade. Inhibition of the blood coagulation through Factor VIII-Factor IX interaction represents an attractive approach for the treatment and prevention of diseases caused by thrombosis. Our research efforts are continued by the synthesis and biological evaluation of cyclic, head to tail peptides, analogs of the 558-565 sequence of the A2 subunit of FVIII, aiming at the efficient inhibition of Factor VIIIa-Factor IXa interaction. The analogs were synthesized on solid phase using the acid labile 2-chlorotrityl chloride resin, while their anticoagulant activities were examined in vitro by monitoring activated partial thromboplastin time and the inhibition of Factor VIII activity. The results reveal that these peptides provide bases for the development of new anticoagulant agents.

Original languageEnglish
Pages (from-to)1087-1096
Number of pages10
JournalAmino Acids
Volume46
Issue number4
DOIs
Publication statusPublished - 1 Apr 2014

Keywords

  • Activated partial thromboplastin time
  • Anticoagulant activity
  • Antithrombotic agents
  • Factor VIII
  • FVIII-FIX interaction
  • Peptoid-peptides
  • Synthetic cyclic peptides

Fingerprint

Dive into the research topics of 'Cyclic peptide analogs of 558-565 epitope of A2 subunit of Factor VIII prolong aPTT. Toward a novel synthesis of anticoagulants'. Together they form a unique fingerprint.

Cite this